
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Pharmaceutical Technology Europe
Click the title above to open the Pharmaceutical Technology Europe May 2016 issue in an interactive PDF format.





